CONNECT WITH US
HealthTech

HealthTech

Alzheimer's blood marker may help estimate cognitive impairment risk up to 10 years ahead

Medical Xpress logo

Published on

Add as a preferred source on Google
Alzheimer's blood marker may help estimate cognitive impairment risk up to 10 years ahead

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

A blood biomarker for Alzheimer's disease may help estimate a cognitively healthy person's risk of developing mild cognitive impairment or dementia over the next five or 10 years, according to a new Mayo Clinic study in JAMA Neurology.

The approach combines a blood measure of phosphorylated Tau 217 (p-tau217), a biomarker associated with Alzheimer's disease, with age, sex and genetic risk to estimate a person's future risk of cognitive impairment. Higher p-tau217 levels and older age were associated with greater risk.

"The goal is to provide a personalized estimate of the risk of developing cognitive impairment that is more meaningful than simply reporting whether a blood test is positive or negative for amyloid pathology," says Alicia Algeciras-Schimnich, Ph.D., a Mayo Clinic laboratory medicine and pathology researcher and first author of the study.

The study builds on previous Mayo Clinic research that used PET brain scans to measure amyloid, a protein that accumulates in the brain in Alzheimer's disease, and predict future cognitive impairment. The new work applies a similar approach using a blood biomarker, which is less invasive and potentially more scalable.

Researchers analyzed 1,644 cognitively unimpaired participants in the Mayo Clinic Study of Aging and 534 participants in the Alzheimer's Disease Neuroimaging Initiative. Participants were ages 60 to 90 and had p-tau217 blood measurements, genetic testing and repeated cognitive assessments over time.

Using the Mayo Clinic Study of Aging data, researchers estimated the likelihood of developing mild cognitive impairment (MCI) or dementia within five and 10 years.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.